CA
NZ
UK
AU
IND
US
Editas Medicine (NASDAQ:EDIT) advanced 9.33% as gene-editing sentiment strengthened and investors reassessed a company that has repositioned itself around in vivo editing after stepping back from an earlier ex vivo focus.
● ELAB shares fell 12.73% following the company's mid-August announcement of an anticipated reverse stock split.
Cumberland Pharmaceuticals (NASDAQ:CPIX) jumped 10.97% to close near $8.70, pushing the specialty pharmaceutical company to fresh 52-week-high territory and capping a powerful multi-month advance. The rally follows a transformative July transaction that recapitalized theBusinessand reoriented its strategy toward clinical development.
Ginkgo Bioworks (NYSE:DNA) surged 11.21% in a session that stood out mainly because the synthetic-biology company has spent much of 2026 grinding lower. The bounce came just weeks after a disappointing second-quarter report that had pressured the shares, suggesting the move was as much …
ClearOne, Inc. (NASDAQ:CLRO), a small-cap audio-conferencing hardware maker, jumped 11.98% as traders continued to reassess a stock that has been transformed by a pending reverse merger. What was once a sleepy communications-equipment name has become a speculative vehicle for a very different business, and …
Compugen (NASDAQ:CGEN), an Israel-based cancer-immunotherapy company, rose 10.81% to about $2.87, roughly doubling from a year earlier and reclaiming attention among biotech traders. The Tel Aviv-headquartered firm has quietly built aBusinessmodel that blends its own clinical programs with lucrative partnerships alongside AstraZeneca and Gilead …
ClearPoint Neuro (NASDAQ:CLPT), a medical-device company that provides navigation and delivery systems for brain therapies, advanced 11.80% as investors revisited a stock that has straddled the line between promising platform play and cash-burning small cap.
Shares of Biodesix (NASDAQ:BDSX), the Colorado-based lung-diagnostics company, jumped 10.58% in a session that put the small-cap name back on the radar of momentum traders and healthcare investors alike. The move came against a backdrop of steadily improving fundamentals, with the company reporting rapid …
Beam Therapeutics (NASDAQ:BEAM) rose 9.53% as gene-editing stocks found renewed momentum and the company advanced its lead base-editing program into a pivotal-stage cohort, reviving interest in a technology that promises precise, single-letter corrections to DNA.
● BIAF shares fell 10.82% without an accompanying negative disclosure, running counter to the company's recently reported operational momentum.
Please wait processing your request...